Citations

Clear

9383 citation(s) found for "Thomas, PS".

Amelioration of High Cardiac Output and Pulmonary Hypertension by Occlusion of Congenital Porto-Systemic Shunt
McCully, Robert B. , Kamath, Patrick S. , Bower, Thomas C., McKusick, Michael A., Lapyere, Andre C., Pereira, Naveen L. , McKie, Paul M.

Mayo Clinic

Circulation | November 20, 2012 | Volume: 126 | Issue: 21 | Pages: 2533-2534

10.1161/circulationaha.112.106609 | PMID 23169255 Get It

Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38
Escande, Carlos , Nin, Verónica , Price, Nathan L. , Capellini, Verena Kise , Gomes, Ana P., Barbosa, Maria Thereza , O’Neil, Luke, White, Thomas A. , Sinclair, David , Chini, Eduardo N. , Sinclair, David A

Mayo Clinic

Diabetes | November 20, 2012 | Volume: 62 | Issue: 4 | Pages: 1084-1093

10.2337/db12-1139 | PMID 23172919 Get It

Metabolic syndrome is a growing health problem worldwide. It is therefore imperative to develop new strategies to treat this pathology. In the past years, the manipulation of NAD+ metabolism has emerged as a plausible strategy to ameliorate metabolic syndrome. In particular, an increase in cellular NAD+ levels has beneficial effects, likely because of the activation of sirtuins. Previously, we reported that CD38 is the primary NAD+ase in mammals. Moreover, CD38 knockout mice have higher NAD+ levels and are protected against obesity and metabolic syndrome. Here, we show that CD38 regulates global protein acetylation through changes in NAD+ levels and sirtuin activity. In addition, we characterize two CD38 inhibitors: quercetin and apigenin. We show that pharmacological inhibition of CD38 results in higher intracellular NAD+ levels and that treatment of cell cultures with apigenin decreases global acetylation as well as the acetylation of p53 and RelA-p65. Finally, apigenin administration to obese mice increases NAD+ levels, decreases global protein acetylation, and improves several aspects of glucose and lipid homeostasis. Our results show that CD38 is a novel pharmacological target to treat metabolic diseases via NAD+-dependent pathways.
Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo‐controlled study
Kelly, Ciarán P. , Green, P. H. R., Murray, Joseph A. , DiMarino, Anthony J., Colatrella, Anthony M., Leffler, Daniel A. , Alexander, T. , Arsenescu, Razvan, Jiang, John , Arterburn, L. A., Paterson, Blake, Fedorak, Richard N. , Group, the Larazotide Acetate Celiac Disease Study, León, Francisco , Group, the Larazotide Acetate Celiac Disease Study, Murray, J A , Fedorak, R N

Mayo Clinic

Alimentary Pharmacology & Therapeutics | November 19, 2012 | Volume: 37 | Issue: 2 | Pages: 252-262

10.1111/apt.12147 | PMID 23163616 Get It

Summary Background Coeliac disease, an autoimmune disorder triggered by gluten ingestion, is managed by a gluten‐free diet ( GFD ), which is difficult for many patients. Larazotide acetate is a first‐in‐class oral peptide that prevents tight junction opening, and may reduce gluten uptake and associated sequelae. Aim To evaluate the efficacy and tolerability of larazotide acetate during gluten challenge. Methods This exploratory, double‐blind, randomised, placebo‐controlled study included 184 patients maintaining a GFD before and during the study. After a GFD run‐in, patients were randomised to larazotide acetate (1, 4, or 8 mg three times daily) or placebo and received 2.7 grams of gluten daily for 6 weeks. Outcomes included an experimental biomarker of intestinal permeability, the lactulose‐to‐mannitol ( LAMA ) ratio and clinical symptoms assessed by Gastrointestinal Symptom Rating Scale ( GSRS ) and anti‐transglutaminase antibody levels. Results No significant differences in LAMA ratios were observed between larazotide acetate and placebo groups. Larazotide acetate 1‐mg limited gluten‐induced symptoms measured by GSRS ( P = 0.002 vs. placebo). Mean ratio of anti‐tissue transglutaminase IgA levels over baseline was 19.0 in the placebo group compared with 5.78 ( P = 0.010), 3.88 ( P = 0.005) and 7.72 ( P = 0.025) in the larazotide acetate 1‐, 4‐, and 8‐mg groups, respectively. Adverse event rates were similar between larazotide acetate and placebo groups. Conclusions Larazotide acetate reduced gluten‐induced immune reactivity and symptoms in patients with coeliac disease undergoing gluten challenge and was generally well tolerated; however, no significant difference in LAMA ratios between larazotide acetate and placebo was observed. Results and design of this exploratory study can inform the design of future studies of pharmacological interventions in patients with coeliac disease.
Stroke After Carotid Stenting and Endarterectomy in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
Hill, Michael D. , Brooks, William H. , Mackey, Ariane , Clark, Wayne M. , Morrish, William, Mohr, J.P. , Rhodes, J. , Popma, Jeffrey J. , Lal, Brajesh K. , Longbottom, Mary, Voeks, Jenifer H. , Howard, George , Brott, Thomas G. , Investigators, for the CREST, Meschia, James F. , Investigators, for the CREST, Hill, Michael D , Howard, George

Mayo Clinic

Circulation | November 18, 2012 | Volume: 126 | Issue: 25 | Pages: 3054-3061

10.1161/circulationaha.112.120030 | PMID 23159552 Get It

Background— Stroke occurs more commonly after carotid artery stenting than after carotid endarterectomy. Details regarding stroke type, severity, and characteristics have not been reported previously. We describe the strokes that have occurred in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). Methods and Results— CREST is a randomized, open-allocation, controlled trial with blinded end-point adjudication. Stroke was a component of the primary composite outcome. Patients who received their assigned treatment within 30 days of randomization were included. Stroke was adjudicated by a panel of board-certified vascular neurologists with secondary central review of clinically obtained brain images. Stroke type, laterality, timing, and outcome were reported. A periprocedural stroke occurred among 81 of the 2502 patients randomized and among 69 of the 2272 in the present analysis. Strokes were predominantly minor (81%, n=56), ischemic (90%, n=62), in the anterior circulation (94%, n=65), and ipsilateral to the treated artery (88%, n=61). There were 7 hemorrhages, which occurred 3 to 21 days after the procedure, and 5 were fatal. Major stroke occurred in 13 (0.6%) of the 2272 patients. The estimated 4-year mortality after stroke was 21.1% compared with 11.6% for those without stroke. The adjusted risk of death at 4 years was higher after periprocedural stroke (hazard ratio, 2.78; 95% confidence interval, 1.63–4.76). Conclusions— Stroke, particularly severe stroke, was uncommon after carotid intervention in CREST, but stroke was associated with significant morbidity and was independently associated with a nearly 3-fold increased future mortality. The delayed timing of major and hemorrhagic stroke after revascularization suggests that these strokes may be preventable. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00004732.
Duodenal Intraepithelial Lymphocytosis With Normal Villous Architecture in Pediatric Patients
Shmidt, Eugenia , Smyrk, Thomas C. , Faubion, William A. , Oxentenko, Amy S.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | November 17, 2012 | Volume: 56 | Issue: 1 | Pages: 51-55

10.1097/mpg.0b013e318267c353 | PMID 22785416 Get It

ABSTRACTObjectives:Small bowel intraepithelial lymphocytosis (IELs) with normal villous architecture is a relatively common finding, often of uncertain significance. The aims of our study were to determine the prevalence of this finding, its clinical associations, its specificity for celiac disease (CD), and whether histologic clues exist that increase the specificity for CD in this setting, all in the pediatric population.Methods:The Mayo Clinic electronic pathology database was searched between January 1, 2000 and December 31, 2009 for patients younger than 18 years who had the terms “normal villi” and “increased intraepithelial lymphocytes” in their small bowel biopsy reports. All of the slides were reviewed to confirm the histologic findings. Demographic, serologic, pathologic, and clinical informations were obtained.Results:Among 1290 duodenal biopsies obtained from children during the years 2000 and 2009, 56 (4.3%) were noted to have “normal villous architecture with increased intraepithelial lymphocytes.” In the 54 patients not known to have CD before biopsy, 48 (89%) had serologic testing for CD. Of these 48 patients, 9 were labeled with CD, although only 5 of 9 met the definite criteria for the diagnosis, based on a combination of serologic markers, human leukocyte antigen haplotyping, and response to gluten‐free diet. No clinical features pointed to a diagnosis of CD. There was no correlation between CD and number of IELs, but patients with newly diagnosed CD were more likely to have a tip‐heavy lymphocyte distribution. Other diagnoses made during the study period and in follow‐up were inflammatory bowel disease (5), Helicobacter pylori infection (3), medication‐related injury (10), and systemic autoimmune disorders (2).Conclusions:Increased IELs with normal villous architecture in small bowel biopsies are clinically important in children, and are associated with a new definite diagnosis of CD in 9% of pediatric patients. Even at this low sensitivity, clinical work‐up for CD is mandated in all of the patients with this finding.
inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations
Schwind, Sebastian , Edwards, Colin G., Mrózek, Krzysztof , Maharry, Kati , Wu, Yue-Zhong, Paschka, Peter , Eisfeld, Ann‐Kathrin , Hoellerbauer, Pia , Becker, Heiko , Metzeler, Klaus H. , Curfman, John, Kohlschmidt, Jessica, Prior, Thomas W., Kolitz, Jonathan E. , Blum, William , Pettenati, Mark J., Cin, Paola Dal , Carroll, Andrew J. , Larson, Richard A. , Volinia, Stefano , Marcucci, Guido , Bloomfield, Clara D. , Nicolet, Deedra , Caligiuri, Michael A. , Larson, Richard A

Mayo Clinic

Blood | November 17, 2012 | Volume: 121 | Issue: 2 | Pages: 385-391

10.1182/blood-2012-07-442772 | PMID 23160462 Get It

Abstract The inv(16)(p13q22)/t(16;16)(p13;q22) in acute myeloid leukemia results in multiple CBFB-MYH11 fusion transcripts, with type A being most frequent. The biologic and prognostic implications of different fusions are unclear. We analyzed CBFB-MYH11 fusion types in 208 inv(16)/t(16;16) patients with de novo disease, and compared clinical and cytogenetic features and the KIT mutation status between type A (n = 182; 87%) and non–type A (n = 26; 13%) patients. At diagnosis, non–type A patients had lower white blood counts (P = .007), and more often trisomies of chromosomes 8 (P = .01) and 21 (P < .001) and less often trisomy 22 (P = .02). No patient with non–type A fusion carried a KIT mutation, whereas 27% of type A patients did (P = .002). Among the latter, KIT mutations conferred adverse prognosis; clinical outcomes of non–type A and type A patients with wild-type KIT were similar. We also derived a fusion-type–associated global gene-expression profile. Gene Ontology analysis of the differentially expressed genes revealed—among others—an enrichment of up-regulated genes involved in activation of caspase activity, cell differentiation and cell cycle control in non–type A patients. We conclude that non–type A fusions associate with distinctclinical and genetic features, including lack of KIT mutations, and a unique gene-expression profile.
Clinical Specificity of the Enzyme Immunoassay Test for Coccidioidomycosis Varies According to the Reason for Its Performance
Blair, Janis E. , Mendoza, Neil, Force, Shannon, Grys, Thomas E. , Chang, Yu‐Hui , Grys, Thomas E

Mayo Clinic

Clinical and Vaccine Immunology | November 17, 2012 | Volume: 20 | Issue: 1 | Pages: 95-98

10.1128/cvi.00531-12 | PMID 23155124 Get It

ABSTRACT The diagnosis of coccidioidomycosis relies heavily on serologic test results in addition to clinical history, physical examination, and radiographic findings. Use of the enzyme immunoassay (EIA) has increased because it is rapidly performed and does not require referral to a reference laboratory, as do complement fixation and immunodiffusion tests. However, interpretation of immunoglobulin M (IgM) reactivity by EIA in the absence of immunoglobulin G (IgG) reactivity has been problematic. We conducted a retrospective medical record review of all patients with such IgM reactivity at our institution to identify situations where the finding was more likely to be clinically specific for coccidioidal infection. From 1 January 2004 through 31 December 2008, a total of 1,117 patients had positive EIA coccidioidal serology or EIA IgM-only reactivity; of these, 102 patients (9%) had EIA IgM-only reactivity. Among the 102 patients with EIA IgM-only reactivity, 60 were tested to evaluate symptomatic illness, 13 for follow-up of previously abnormal serology, and 29 for screening purposes. Of the 102 patients, 80 (78%) had positive serologic findings by other methods or had positive culture or histology. Fifty-four (90%) of the 60 patients whose serology was performed to evaluate symptomatic illness had coccidioidal infection, whereas 13 (45%) of 29 patients whose serology was performed for screening purposes had coccidioidal infection. Of the 102 patients with isolated IgM reactivity by EIA, 12 later seroconverted to IgG and IgM reactivity. The use of EIA for screening in 29 asymptomatic persons was associated with unconfirmable results in 13 (45%). Although the majority of patients in our study with isolated IgM reactivity by EIA had probable or confirmed coccidioidomycosis, this result must be interpreted with caution for asymptomatic patients.
Usefulness of R.E.N.A.L. Nephrometry Scoring System for Predicting Outcomes and Complications of Percutaneous Ablation of 751 Renal Tumors
Schmit, Grant D. , Thompson, R. Houston, Weisbrod, Adam J. , Boorjian, Stephen A. , Carter, Rickey E. , Geske, Jennifer R. , Callstrom, Matthew R. , Atwell, Thomas D. , Kurup, A. Nicholas , Carter, Rickey E , Geske, Jennifer

Mayo Clinic

Journal of Urology | November 16, 2012 | Volume: 189 | Issue: 1 | Pages: 30-35

10.1016/j.juro.2012.08.180 | PMID 23164375 Get It

Cognitive Impairment Occurs in Children and Adolescents With Multiple Sclerosis
Julián, Laura , Serafin, Dana, Charvet, Leigh , Ackerson, Joseph, Braaten, Ellen B. , Brown, Tanya M. , O’Donnell, Ellen , Parrish, Joy , Preston, Thomas, Zaccariello, Michael J. , Belman, Anita , Gorman, Mark , Ness, Jayne , Patterson, Marc C. , Rodriguez, Moses , Yeh, E. Ann , Krupp, Lauren , Benedict, Ralph H. B. , Chitnis, Tanuja , Waubant, Emmanuelle L. , Weinstock‐Guttman, Bianca , Krupp, Lauren , Rodriguez, Moses , Charvet, Leigh E , Patterson, Marc

Mayo Clinic

Journal of Child Neurology | November 15, 2012 | Volume: 28 | Issue: 1 | Pages: 102-107

10.1177/0883073812464816 | PMID 23155206 Get It

In the largest sample studied to date, we measured cognitive functioning in children and adolescents with pediatric multiple sclerosis (n = 187) as well as those with clinically isolated syndrome (n = 44). Participants were consecutively enrolled from six United States Pediatric Multiple Sclerosis Centers of Excellence. Participants had a mean of 14.8 ± 2.6 years of age and an average disease duration of 1.9 ± 2.2 years. A total of 65 (35%) children with multiple sclerosis and 8 (18%) with clinically isolated syndrome met criteria for cognitive impairment. The most frequent areas involved were fine motor coordination (54%), visuomotor integration (50%), and speeded information processing (35%). A diagnosis of multiple sclerosis (odds ratio = 3.60, confidence interval = 1.07, 12.36, P = .04) and overall neurologic disability (odds ratio = 1.47, confidence interval = 1.10, 2.10, P = .03) were the only independent predictors of cognitive impairment. Cognitive impairment may occur early in these patients, and prompt recognition is critical for their care.
Elbow Resection for Deep Infection After Total Elbow Arthroplasty
Sotelo, Joaquín Sánchez, Zarkadas, Peter C., Throckmorton, Thomas, Morrey, B.F.

Mayo Clinic

JBJS Essential Surgical Techniques | November 15, 2012 | Volume: 2 | Issue: 1 | Pages: e5

10.2106/jbjs.st.k.00017 | PMID 31321128 Get It